S&P 500   3,257.87 (+0.65%)
DOW   26,875.29 (+0.42%)
QQQ   266.68 (+0.95%)
AAPL   109.60 (+2.32%)
MSFT   204.54 (+1.97%)
FB   250.59 (+0.63%)
GOOGL   1,428.20 (+1.33%)
AMZN   3,049.44 (+1.65%)
NVDA   499.97 (+3.10%)
TSLA   391.91 (+3.04%)
BABA   269.84 (-1.14%)
CGC   14.44 (-1.10%)
GE   6.05 (-0.98%)
MU   49.52 (-0.66%)
AMD   76.70 (+2.64%)
T   27.89 (+0.07%)
F   6.59 (-0.75%)
ACB   5.19 (+0.39%)
GILD   62.23 (-1.36%)
NFLX   472.89 (+0.48%)
DIS   122.42 (-0.70%)
BAC   23.30 (+0.17%)
BA   145.53 (-3.74%)
S&P 500   3,257.87 (+0.65%)
DOW   26,875.29 (+0.42%)
QQQ   266.68 (+0.95%)
AAPL   109.60 (+2.32%)
MSFT   204.54 (+1.97%)
FB   250.59 (+0.63%)
GOOGL   1,428.20 (+1.33%)
AMZN   3,049.44 (+1.65%)
NVDA   499.97 (+3.10%)
TSLA   391.91 (+3.04%)
BABA   269.84 (-1.14%)
CGC   14.44 (-1.10%)
GE   6.05 (-0.98%)
MU   49.52 (-0.66%)
AMD   76.70 (+2.64%)
T   27.89 (+0.07%)
F   6.59 (-0.75%)
ACB   5.19 (+0.39%)
GILD   62.23 (-1.36%)
NFLX   472.89 (+0.48%)
DIS   122.42 (-0.70%)
BAC   23.30 (+0.17%)
BA   145.53 (-3.74%)
S&P 500   3,257.87 (+0.65%)
DOW   26,875.29 (+0.42%)
QQQ   266.68 (+0.95%)
AAPL   109.60 (+2.32%)
MSFT   204.54 (+1.97%)
FB   250.59 (+0.63%)
GOOGL   1,428.20 (+1.33%)
AMZN   3,049.44 (+1.65%)
NVDA   499.97 (+3.10%)
TSLA   391.91 (+3.04%)
BABA   269.84 (-1.14%)
CGC   14.44 (-1.10%)
GE   6.05 (-0.98%)
MU   49.52 (-0.66%)
AMD   76.70 (+2.64%)
T   27.89 (+0.07%)
F   6.59 (-0.75%)
ACB   5.19 (+0.39%)
GILD   62.23 (-1.36%)
NFLX   472.89 (+0.48%)
DIS   122.42 (-0.70%)
BAC   23.30 (+0.17%)
BA   145.53 (-3.74%)
S&P 500   3,257.87 (+0.65%)
DOW   26,875.29 (+0.42%)
QQQ   266.68 (+0.95%)
AAPL   109.60 (+2.32%)
MSFT   204.54 (+1.97%)
FB   250.59 (+0.63%)
GOOGL   1,428.20 (+1.33%)
AMZN   3,049.44 (+1.65%)
NVDA   499.97 (+3.10%)
TSLA   391.91 (+3.04%)
BABA   269.84 (-1.14%)
CGC   14.44 (-1.10%)
GE   6.05 (-0.98%)
MU   49.52 (-0.66%)
AMD   76.70 (+2.64%)
T   27.89 (+0.07%)
F   6.59 (-0.75%)
ACB   5.19 (+0.39%)
GILD   62.23 (-1.36%)
NFLX   472.89 (+0.48%)
DIS   122.42 (-0.70%)
BAC   23.30 (+0.17%)
BA   145.53 (-3.74%)
Log in

15 Healthcare Stocks that Analysts Love in 2020

Posted on Thursday, September 24th, 2020 by MarketBeat Staff
There are more than 200 healthcare companies traded on public markets. Given the sheer number of pharmaceutical companies, medical research firms, hospital systems and other healthcare stocks, it can be hard to identify which healthcare companies are going to outperform the market.

Fortunately, Wall Street's brightest minds have already done this for us. Every year, analyst issue approximately 3,000 distinct recommendations for healthcare companies. Analysts don't always get their "buy" ratings right, but it's worth taking a hard look when several analysts from different brokerages and research firm are giving "strong buy" and "buy" ratings to the same healthcare stock.

This slide show lists the 15 healthcare companies that have the highest average analyst recommendations from Wall Street's equities research analysts over the last 12 months.

#1 - Legend Biotech (NASDAQ:AMTI)

Consensus Rating: Buy
Rating Score: 3.0
Ratings Breakdown: 4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $34.50 (15.5% Upside)

Legend Biotech logoApplied Molecular Transport Inc develops biological therapeutics to treat autoimmune, metabolic, and inflammatory diseases.. The company develops submucosal biopharmaceuticals and bio-betters. Applied Molecular Transport Inc was incorporated in 2010 and is based in South San Francisco, California.


#2 - LHC Group (NASDAQ:LHCG)

Consensus Rating: Buy
Rating Score: 2.8
Ratings Breakdown: 6 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $191.43 (-4.8% Upside)

LHC Group logoLHC Group, Inc provides post-acute health care services to patients through its home nursing agencies, hospices and long-term acute care hospitals. The company operates through the following business segments: Home Health Services, Hospice Services, Home & Community-Based Services, Facility-Based Services and Healthcare Innovations. Read More 

#3 - Repligen (NASDAQ:RGEN)

Consensus Rating: Buy
Rating Score: 3.2
Ratings Breakdown: 6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $139.50 (-0.7% Upside)

Repligen logoRepligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process in North America, Europe, APAC, and internationally. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media. Read More 

#4 - Interpace Diagnostics Group (NASDAQ:IDXG)

Consensus Rating: Buy
Rating Score: 3.0
Ratings Breakdown: 5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $8.81 (190.8% Upside)

Interpace Diagnostics Group logoInterpace Biosciences, Inc provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. Read More 

#5 - Teleflex (NYSE:TFX)

Consensus Rating: Buy
Rating Score: 2.9
Ratings Breakdown: 9 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $389.40 (18.3% Upside)

Teleflex logoTeleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It offers vascular access products that comprise Arrow branded catheters and related devices, including catheter positioning systems for use in the administration of intravenous medications and other therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site; and devices for treating coronary and peripheral vascular disease. Read More 

#6 - Trulieve Cannabis (OTCMKTS:TCNNF)

Consensus Rating: Buy
Rating Score: 3.0
Ratings Breakdown: 7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $33.38 (91.7% Upside)

Trulieve Cannabis logoTrulieve Cannabis Corp. operates as a medical marijuana company. The company cultivates and produces products in-house and distributes its products to Trulieve branded stores (dispensaries) in Florida, as well as directly to patients via home delivery. It produces approximately 150 stock keeping units, including nasal sprays, capsules, concentrates, syringes, cannabis flower in tamper-proof containers for vaporizers, topical creams, tinctures, and vape cartridge. Read More 

#7 - Forte Biosciences (NASDAQ:FBRX)

Consensus Rating: Buy
Rating Score: 3.0
Ratings Breakdown: 6 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $85.00 (80.6% Upside)

Forte Biosciences logoForte Biosciences, Inc operates as a biotechnology company. The company was founded in 2017 and is based in Sherman Oaks, California.

#8 - DarioHealth (NASDAQ:DRIO)

Consensus Rating: Buy
Rating Score: 3.0
Ratings Breakdown: 3 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $17.33 (8.0% Upside)

DarioHealth logoDarioHealth Corp., a digital health company, develops and commercializes patented and proprietary technologies providing consumers with laboratory-testing capabilities using smart phones and other mobile devices in the United States, Europe, Australia, and Canada. The company's flagship product, Dario, also known as Dario Smart Diabetes Management Solution, is a mobile, real-time, cloud-based, diabetes management solution based on a software application combined with Dario Smart Meter, a pocket-sized, blood glucose monitoring device. Read More 

#9 - Iterum Therapeutics (NASDAQ:NRBO)

Consensus Rating: Buy
Rating Score: 3.0
Ratings Breakdown: 2 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $20.00 (271.7% Upside)

Iterum Therapeutics logoNeuroBo Pharmaceuticals, Inc provides novel therapies for diabetic neuropathic pain and central nervous system diseases. NeuroBo Pharmaceuticals, Inc was founded in 2017 and is based in Boston, Massachusetts.

#10 - Poseida Therapeutics (NASDAQ:PSTX)

Consensus Rating: Buy
Rating Score: 3.0
Ratings Breakdown: 4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $23.33 (148.0% Upside)

Poseida Therapeutics logoPoseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company is developing a pipeline of solutions for the treatment of hematological malignancies and solid tumors, as well as vivo programs for liver-directed gene therapies for rare diseases. Read More 

#11 - Sanofi (OTCMKTS:SNYNF)

Consensus Rating: Buy
Rating Score: 3.0
Ratings Breakdown: 4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: N/A

Sanofi logoSanofi provides therapeutic solutions worldwide. It offers Cerezyme and Cerdelga for Gaucher, Myozyme and Lumizyme for Pompe, Fabrazyme for Fabry, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio, an immunomodulatory and Lemtrada, a monoclonal antibody for multiple sclerosis. It also provides Dupixent for atopic dermatitis; Kevzara for rheumatoid arthritis; Eloctate and Alprolix to treat hemophilia; and Cablivi to treat acquired thrombotic thrombocytopenic purpura. Read More 

#12 - 9 Meters Biopharma (NASDAQ:NMTR)

Consensus Rating: Buy
Rating Score: 3.0
Ratings Breakdown: 4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $5.00 (613.9% Upside)

9 Meters Biopharma logo9 Meters Biopharma, Inc operates as a rare, orphan, and unmet needs-focused GI company. The company is advancing its drug candidates for short bowel syndrome and celiac disease. Its product candidates include NM-002, a proprietary long-acting GLP-1 agonist into Phase 2 trial for short bowel syndrome; and larazotide, a Phase 3 tight junction regulator being evaluated for patient-reported symptom improvement in non-responsive celiac disease. Read More 

#13 - Terrascend (OTCMKTS:TRSSF)

Consensus Rating: Buy
Rating Score: 3.0
Ratings Breakdown: 4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $6.00 (44.2% Upside)

Terrascend logoTerrAscend Corp., a biopharmaceutical and wellness company, engages in the cultivation, development, and sale of medical cannabis in Canada. The company offers its cannabis products under the Knüba Naturals brand. It also provides education and support programs to physicians and patients through health care professionals. Read More 

#14 - Nkarta (NASDAQ:ANNX)

Consensus Rating: Buy
Rating Score: 3.0
Ratings Breakdown: 5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $33.00 (43.0% Upside)

Nkarta logoAnnexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune and neurodegenerative diseases. It focuses on the treatment of body, brain, and eye disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Read More 

#15 - Inventiva (NYSE:IVA)

Consensus Rating: Buy
Rating Score: 3.0
Ratings Breakdown: 4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target: $27.33 (144.5% Upside)

Inventiva logoInventiva SA, a biopharmaceutical company, develops drugs for the treatment of fibrotic, cancer, and orphan diseases. Its lead product candidate is Lanifibranor that is in Phase IIb clinical trial to treat nonalcoholic steatohepatitis and systemic sclerosis. The company also develops Odiparcil, which is in Phase IIa clinical trial primarily for the treatment of mucopolysaccharidosis type VI disease; YAP-TEAD that is in preclinical stage to treat malignant mesothelioma and lung cancer; NSD2 for the treatment of multiple myeloma; and EPICURE for immuno-oncology treatment. Read More 

 

5 Travel Company Stocks Likely to Suffer From the Coronavirus

How important is the global travel and tourism industry? It’s a sector that accounts for about 10% of the world’s adult workforce. That’s 350 million people. The industry also accounts for at least 4% of the global gross domestic product (GDP).

In short, it’s an industry that accounts for trillions of dollars for the economy. And it relies on the most visible workers like pilots and cruise ship captains to the kitchen and housecleaning staff and servers. The travel industry is in many ways a service industry. But when there’s nobody to service, these businesses take a tumble.

And tumble it has. The world is going through a period of enforced social distancing. Many countries are taking even more extreme measures to lock down parts, or all, of their countries in an effort to contain the spread of the coronavirus and to flatten the curve to prevent healthcare workers and hospitals from being overwhelmed.

But that means fewer people are flying. Planned vacations are being canceled. And all of this is bad news for a sector that relies on the mobility of global travelers.

To be fair, the best of these companies should recover just fine. However, some of these companies had fundamental concerns that will be magnified by the loss of revenue.

View the "5 Travel Company Stocks Likely to Suffer From the Coronavirus" Here.






Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.